Veracyte Names Angeline McCabe as Vice President, Investor Relations and Corporate Communications
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug 29, 2018--Veracyte, Inc. (Nasdaq: VCYT) today announced that the company has named Angeline (“Angie”) McCabe as vice president, investor relations and corporate communications, effective immediately. In this role, Ms. McCabe will be responsible for the development and execution of Veracyte’s communications strategy to internal and external stakeholders, including shareholders, customers, and employees.
Prior to joining Veracyte, Ms. McCabe served as vice president, investor relations at WellCare Health Plans, Inc. Previously, she held investor relations and corporate communications positions at companies including Health Net, Valeant Pharmaceuticals and WellPoint Health Networks.
“I am excited to welcome Angie to the Veracyte team. Her more than 20 years of investor relations and communications experience, as well as her strong leadership skills and health care background, will help advance our company’s broader strategic goals,” said Bonnie Anderson, chairman and chief executive officer of Veracyte. “In particular, Angie’s experience in building investor relations and communications programs to support business growth will be a valuable asset to the company.”
Ms. McCabe holds a Bachelor of Arts degree in History from California Polytechnic State University, San Luis Obispo and an Investor Relations Charter™. She is an active member in the National Investor Relations Institute (NIRI), the world’s largest professional association of investor relations practitioners, and served as a NIRI national board member from December 2013 through December 2017.
Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that improves patient care by providing trustworthy and actionable answers to challenging clinical questions. The company’s products uniquely combine advanced genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward, informing both diagnosis and treatment decisions without the need for costly, risky surgeries that are often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180829005651/en/
CONTACT: Veracyte, Inc.
Tracy Morris, 650-380-4413
Keith Kennedy, 650-243-6357
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT SOFTWARE HEALTH BIOTECHNOLOGY GENETICS ONCOLOGY RESEARCH SCIENCE
SOURCE: Veracyte, Inc.
Copyright Business Wire 2018.
PUB: 08/29/2018 04:05 PM/DISC: 08/29/2018 04:05 PM